Effects of bone matrix proteins on fracture and fragility in osteoporosis

Current Osteoporosis Reports

Volumn 10, Issue 2, 2012, Pages 141-150

  Sroga, Grazyna E ^a   Vashishth, Deepak ^a  

^a RENSSELAER POLYTECHNIC INSTITUTE   (United States)

Author keywords

Collagens; Extracellular bone matrix; Fragility fractures; Glycation; Noncollagenous proteins; Osteoporosis

Indexed keywords

BONE SIALOPROTEIN; COLLAGEN; COLLAGEN TYPE 1; COLLAGEN TYPE 3; COLLAGEN TYPE 5; COLLAGEN TYPE 6; DENTIN SIALOPHOSPHOPROTEIN; FIBRILLIN; FIBRONECTIN; MATRIX EXTRACELLULAR PHOSPHOGLYCOPROTEIN; MATRIX PROTEIN; NONCOLLAGENOUS PROTEIN; OSTEOCALCIN; OSTEONECTIN; OSTEOPONTIN; THROMBOSPONDIN 2; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ARTICLE; BIOMECHANICS; BONE DENSITY; BONE FRAGILITY; BONE STRENGTH; CELL CYCLE PROGRESSION; CELL DIFFERENTIATION; CELL GROWTH; CELL SURVIVAL; EXTRACELLULAR MATRIX; FRACTURE; GLYCATION; HUMAN; NONHUMAN; OSTEOPOROSIS; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN SYNTHESIS; PROTEOMICS; RISK ASSESSMENT;

ANIMALS; BIOMECHANICS; BONE DENSITY; BONE MATRIX; COLLAGEN; FRACTURES, BONE; HUMANS; MODELS, ANIMAL; OSTEOPOROSIS; RISK FACTORS;

EID: 84865745554     PISSN: 15441873     EISSN: 15442241     Source Type: Journal    
DOI: 10.1007/s11914-012-0103-6     Document Type: Article

References (98)

1. Young MF. Bone matrix proteins: their function, regulation, and relationship to osteoporosis. Osteoporos Int. 2003;14 Suppl 3: S35-42.
2. Schuit SC, van der Klift M, Weel AE, et al. Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam study. Bone. 2004;34:195-202. (Pubitemid 38142449)
3. Ott SM. When bone mass fails to predict bone failure. Calcif Tissue Int. 1993;53:S7-S13. (Pubitemid 23277161)
4. Sellmeyer DE. Atypical fractures as a potential complication of long-termbisphosphonate therapy. J Am Med Assoc. 2010;304: 1480-3.
5. Yoon RS, Hwang JS, Beebe K. Long-term bisphosphonate usage and subtrochanteric insuffciency fractures: a cause for concern? J Bone Joint Surg Br. 2011;93:1289-95.
6. Ahlman MA, Rissing MS, Gordon L. Evolution of bisphosphonate related atypical fracture retrospectively observed with DXA scanning. J Bone Miner Res. 2012;27(2):496-8.
7. Melton 3rd LJ, Riggs BL, Keaveny TM, et al. Structural determinants of vertebral fracture risk. J Bone Miner Res. 2007;22 (12):1885-92. (Pubitemid 351229305)
8. Vashishth D. Rising crack growth resistance behavior in cortical bone: Implications for toughness measurements. J Biomech. 2004;37(10):943-6. (Pubitemid 38521217)
9. Saito M, Fujii K, Soshi S, Tanaka T. Reductions in degree of mineralization and enzymatic collagen cross-links and increases in glycation-induced pentosidine in the femoral neck cortex in cases of femoral neck fracture. Osteoporos Int. 2006;17(7):986-95. (Pubitemid 43864852)
10. Vashishth D. The role of the collagen matrix in skeletal fragility. Curr Osteoporos Rep. 2007;5(2):62-6. (Pubitemid 46954743)
11. Tang SY, Allen MR, Phipps R, et al. Changes in non-enzymatic glycation and its association with altered mechanical properties following 1-year treatment with risedronate or alendronate. Osteoporosis Int. 2009;20(6):887-94.
12. Sornay-Rendu E, Boutroy S, Munoz F, Delmas PD. Alterations of cortical and trabecular architecture are associated with fractures in postmenopausal women, partially independent of decreased BMD measured by DXA: the OFELY study. J Bone Miner Res. 2007;22 (3):425-33. (Pubitemid 46797126)
13. Bornstein P. Matricellular proteins: an overview. J Cell Commun Signal. 2009;3:163-5.
14. Centrella M, Horowitz MC, Wozney JM, et al. Transforming growth factor-beta gene family members and bone. Endocr Rev. 1994;15:27-39.
15. Daughaday W, Rotwein P. Insulin-like growth factors I and II. Peptide, messenger ribonucleic acid and gene structures, serum, and tissue concentrations. Endocr Rev. 1989;10(1):68-91. (Pubitemid 19156368)
16. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev. 1995;16(1): 3-34.
17. Bragdon B, Moseychuk O, Saldanha S, et al. Bone morphogenetic proteins: a critical review. Cell Signal. 2011;23:609-20.
18. Pannicia R, Riccioni T, Zani BM, et al. calcitonin down-regulates immediate cell signals induced in human osteoclast-like cells by the bone sialoprotein-HA fragment through a post-integrin receptor mechanism. Endocrinology. 1995;136:1177-86.
19. Takeuchi Y, Kodama Y, Matsumoto T. Bone matrix decorin binds transforming growth factor-beta and enhances its bioactivity J Biol Chem. 1994;269:32634-8.
20. Staal A, Van Wijnen AJ, Desai RK, et al. Antagonistic effects of transforming growth factor-beta on vitamin D3 enhancement of osteocalcin and osteopontin transcription: reduced interactions of vitamin D receptor/retinoid X receptor complexes with vitamin E response elements. Endocrinology. 1996;137(5):2001-11.
21. Keene DR, Sakai LY, Burgeson RE. Human bone contains type III collagen, type VI collagen, and fibrillin: type III collagen is present onspecific fibers that may mediate attachment of tendons, ligaments, and periosteum to calcified bone cortex. J Histochem Cytochem. 1991;39(1):59-69.
22. Wu JJ, Weis MA, Kim LS, et al. Differences in chain usage and cross-linking specificities of cartilage type V/XI collagen isoforms with age and tissue. J Biol Chem. 2009;284:5539-45.
23. McNally A, Henry Schwarcz HP, Botton GA et al.: A model for the ultrastructure of bone based on electron microscopy of ionmilled sections. PLoS One 7(1):e29258. doi:10.1371/journal. pone.0029258.
24. Chen PY, Toroian D, Price PA, McKittrick J. Minerals form a continuum phase in mature cancellous bone. Calcif Tissue Int. 2011;88:351-61.
25. Singh P, Carraher C, Schwarzbauer JE. Assembly of fibronectin extracellular matrix. Annu Rev Cell Dev Biol. 2010;26:397-419. doi:10.1146/annurev-cellbio-100109-104020.
26. Miner JH, Yurchenco PD. Laminin functions in tissue morphogenesis. Annu Rev Cell Dev Biol. 2004;20:255-84. doi:10.1146/annurev.cellbio.20.010403.094555. (Pubitemid 39488639)
27. Durbeej M. Laminins. Cell Tissue Res. 2010;339(1):259-68. doi: 10.1007/s00441-009-0838-2.
28. Lamoureux F, Baud'huin M, Duplomb L, et al. Proteoglycans: key partners in bone cell biology. Bioessays. 2007;29(8):758-71. (Pubitemid 47204281)
29. Siebers MC, ter Brugge PJ, Walboomers XF, et al. Integrins as linker proteins between osteoblasts and bone replacing materials. A critical review. Biomaterials. 2005;26(2):137-46. (Pubitemid 38789096)
30. LeBaron RG, Höök A, Esko JD, et al. Binding of heparin sulfate to type V collagen. J Biol Chem. 1989;264:7950-6.
31. Conover CA. In vitro studies of insulin-like growth factor I and bone. Growth Horm IGF Res. 2000;Supplement B:S107-10. (Pubitemid 30637226)
32. Conover CA. Regulation and physiological role of insulin-like growth factor binding proteins. Endocr J. 1996;43(Suppl): S43-8. (Pubitemid 27014287)
33. Xia Y, Schneyer AL. The biology of activin: recent advances in structure, regulation and function. J Endocrinol. 2009;202:1-12.
34. Aleman-Muench GR, Soldevila G. When versatility matters: activins/inhibins as key regulators of immunity. Immunol Cell Biol. 2012;90:137-48. doi:10.1038/icb.2011.32.
35. Jenny A, Visser JA, de Jong FH, Laven JSE, et al. Anti-Müllerian hormone: a new marker for ovarian function. Reproduction. 2006;131:1-9. doi:rep.1.00529/rep.1.00529. (Pubitemid 43230697)
36. Visser JA, Schipper I, Laven JSE, et al.: Anti-Müllerian hormone: an ovarian reserve marker in primary ovarian insufficiency. Nat Rev Endocrinol. 2012: doi:10.1038/nrendo.2011.224
37. Assoian RK, Komoriya A, Meyers CA, et al. Transforming growth factor-β in human platelets. Identification of a major storage site, purification, and characterization. J Biol Chem. 1983;258:7155-60. (Pubitemid 13059967)
38. Seyedin SM, Thomas TC, Thompson AY, et al. Purification and characterization of two cartilage-inducing factors from bovine demineralized bone. Proc Natl Acad Sci USA. 1985;82:2267-71. (Pubitemid 15064468)
39. Hering S, Isken E, Knabbe C, et al. TGF-β1 and TGF-β2 mRNA and protein expression in human bone samples. Exp Clin Endocrinol Diabetes. 2001;109:217-26. (Pubitemid 32577689)
40. ten Dijke P, Hill CS. New insights into TGF-β-Smad signalling. Trends Biochem Sci. 2004;29:265-73.
41. Borton AJ, Frederick JP, Datto MB, et al. The loss of Smad3 results in a lower rate of bone formation and osteopenia through dysregulation of osteoblast differentiation and apoptosis. J Bone Miner Res. 2001;16:1754-64. (Pubitemid 32911480)
42. Janssens K, ten Dijke P, Janssens S, et al. Transforming growth factor-β1 to the bone. Endocr Rev. 2005;26(6):743-74.
43. Balooch G, Balooch M, Nalla RK, et al. TGF-β regulates the mechanical properties and composition of bone matrix. Proc Natl Acad Sci USA. 2005;102(52):18813-8. (Pubitemid 43049527)
44. Filvaroff E, Erlebacher A, Ye J, et al. Inhibition of TGF-beta receptor signaling in osteoblasts leads to decreased bone remodeling and increased trabecular bone mass. Development (Cambridge, UK). 1999;126:4267-79. (Pubitemid 29509342)
45. Kavukcuoglu NB, Denhardt DT, Guzelsu N, Mann AB. Osteopontin deficiency and aging on nanomechanics of mouse bone. J Biomed Mater Res. 2007;83:136-44. (Pubitemid 47435658)
46. Mochida Y, Parisuthiman D, Pornprasertsuk-Damrongsri S, et al. Decorin modulates collagen matrix assembly and mineralization. Matrix Biol. 2009;28:44-52.
47. Olszta MJ, Cheng X, Jee SS, et al. Bone structure and formation: a new perspective. Mater Sci Eng Rev. 2007;58:77-116. (Pubitemid 350051885)
48. Qiu SR, Wierzbicki A, Orme CA, et al. Molecular modulation of calcium oxalate crystallization by osteopontin and citrate. Proc Natl Acad Sci USA. 2004;101(7):1811-5. (Pubitemid 38228973)
49. Poundarik A, Karim L, Gundberg C, Vashishth, D.: The role of osteocalcin in bone fracture. Proceedings of the 55th Meeting of the Orthopaedic Research Society, Las Vegas, USA, February, 22-25, 2009 [abstract 724].
50. Sodek J, Ganss B, McKee MD. Osteopontin. Crit Rev Oral Biol Med. 2000;11(3):279-303.
51. McKee MD, Nanci A. Osteopontin deposition in remodeling bone: an osteoblast mediated event. J Bone Miner Res. 1996;11:873-4.
52. Rittling SR, Matsumoto HN, McKee MD, et al. Mice lacking osteopontin show normal development and bone structure but display altered osteoclast formation in vitro. J Bone Miner Res. 1998;13(7):1101-11. (Pubitemid 28311778)
53. Thurner PJ, Erickson B, Jungmann R, et al. High speed photography of compressed human trabecular bone correlates whitening to microscopic damage. Eng Fract Mech. 2007;74:1928-41. (Pubitemid 46534799)
54. Fantner GE, Hassenkam T, Kindt JH, et al. Sacrificial bonds and hidden length dissipate energy as mineralized fibrils separate during bone fracture. Nat Mater. 2005;4:612-6. (Pubitemid 41092691)
55. Fantner GE, Adams J, Turner P, et al. Nanoscale ion mediated networks in bone: osteopontin can repeatedly dissipate large amounts of energy. Nano Lett. 2007;7:2491-8. (Pubitemid 47310151)
56. Sroga GE, Karim L, Colón W, Vashishth D. Biochemical characterization of major bone-matrix proteins using nanoscale-size bone samples and proteomics methodology. Mol Cell Proteomics. 2011;10(9):1-12. doi:10.1074/mcp.M110.006718.
57. Thurner PJ, Chen CG, Ionova-Martin S, et al. Osteopontin deficiency increases bone fragility but preserves bone mass. Bone. 2010;46:1564-73.
58. Weinreb M, Shinar D, Rodan GA. Different pattern of alkaline phosphatase, osteopontin, and osteoealcin expression in developing rat bone visualized by in situ hybridization. J Bone Miner Res. 1990;5:831-42. (Pubitemid 20294767)
59. Boivin G, Morel G, Lian JB, et al. Localization of endogenous osteocalcin in neonatal rat bone and its absence in articular cartilage: effect of warfarin treatment. Virchows Arch A Pathol Anat. 1990;417:505-12.
60. Ducy P, Desbois C, Boyce B, et al. Increased bone formation in osteocalcin-deficient mice. Nature. 1996;382:448-52. (Pubitemid 26264860)
61. Kazanecki CC, Uzwiak DJ, Denhardt DT. Control of osteopontin signaling and function by post-translational phosphorylation and protein folding. J Cell Biochem. 2007;102:912-24. (Pubitemid 350036931)
62. Termine JD, Kleinman HK, Whitson SW, et al. Osteonectin, a bone-specific protein linking mineral to collagen. Cell. 1981;26 (10, 1 Pt 1):99-105. (Pubitemid 12229368)
63. Delany AM, Amling M, Priemel M, et al. Osteopenia and decreased bone formation in osteonectin-defcient mice. J Clin Invest. 2000;105:915-23. (Pubitemid 30203064)
64. Young MF, Kerr JM, Ibaraki K, et al. Structure, expression, and regulation of the major noncollagenous matrix proteins of bone. Clin Orthop. 1992;281:275-94.
65. Lane TF, Sage EH. The biology of SPARC, a protein that modulated cell-matrix interactions. FASEB J. 1994;8:163-73. (Pubitemid 24067139)
66. Shankavaram UT, DeWitt DL, Funk SE, et al. Regulation of human monocyte matrix metalloproteinases by SPARC. J Cell Physiol. 1997;173:327-34. (Pubitemid 27481089)
67. Tremble PM, Lane TF, Sage EH, Werb Z. SPARC, a secreted protein associated with morphogenesis and tissue remodeling, induces expression of metalloproteinases in fibroblasts through a novel extracellular matrix-dependent pathway. J Cell Biol. 1993;121:1433-44. (Pubitemid 23174558)
68. Maillard C, Malaval L, Delmas PD. Immunological screening of SPARC/Osteonectin in nonmineralized tissues. Bone. 1992;13 (3):257-64.
69. Butler W. The nature and significance of osteopontin. Connect Tiss Res. 1989;23:123-36.
70. Gilmour DT, Lyon GJ, Carlton MB, et al. Mice deficient for the secreted glycoprotein SPARC/osteonectin/BM40 develop normally but show severe age-onset cataract formation and disruption of the lens. EMBO J. 1998;17:1860-70. (Pubitemid 28154517)
71. Norose K, Clark JI, Syed NA, et al. SPARC deficiency leads to early onset cataractogenesis. Invest Ophthalmol Vis Sci. 1998;39:2674-80. (Pubitemid 28558226)
72. Margolis RN, Canalis E, Partridge NC. Anabolic hormones in bone: basic research and therapeutic potential. J Clin Endocrinol Metab. 1996;81:872-7. (Pubitemid 26083938)
73. Baron RE. Anatomy and ultrastructure of bone. In: Favus MJ, editor. Primer on the metabolic bone diseases and disorders of mineral metabolism. New York: Lippincott-Raven; 1996. p. 3-10.
74. Ninomiya JT, Tracy RP, Calore JD, et al. Heterogeneity of human bone. J Bone Miner Res. 1990;5:933-8. (Pubitemid 20307110)
75. Delany AM, McMahon DJ, Powell JS, et al. Osteonectin/SPARC polymorphisms in Caucasian men with idiopathic osteoporosis. Osteoporos Int. 2008;19(7):969-78.
76. Muriel MP, Bonaventure J, Stanescu R, et al. Morphological and biochemical studies of a mouse mutant (fro/fro) with bone fragility. Bone. 1991;12:241-8.
77. Ramirez F, Rifkin DB. Extracellular microfibrils: contextual platforms for TGF-β and BMP signaling. Curr Opin Cell Biol. 2009; 21:616-22.
78. Nistala H, Lee-Arteaga S, Smaldone S, et al. Fibrillin-1 and -2 differentially modulate endogenous TGF-β and BMP bioavailability during bone formation. J Cell Biol. 2010;190:1107-21.
79. Ramirez F. Extracellular matrix in the skeleton. In: Pourquie O, editor. The skeletal system. Cold Spring Harbor: Cold Spring Harbor Laboratory Press; 2009. p. 341-53.
80. Nistala H, Lee-Arteaga S, Smaldone S, et al. Extracellular microfibrils modulate osteoblast-supported osteoclastogenesis by restricting TGF-β stimulation of RANKL production. J Biol Chem. 2010; 285:34126-33.
81. Arteaga-Solis E, Sui-Arteaga L, Kim M, et al. Material and mechanical properties of bones deficient for fibrillin-1 or fibrillin-2 microfibrils. Matrix Biol. 2011;30(3):188-94.
82. Diab T, Condon KW, Burr DB, Vashishth D. Age-related change in the damage morphology of human cortical bone and its role in bone fragility. Bone. 2006;38(3):427-31. (Pubitemid 43255437)
83. Diab T, Vashishth D. Morphology, localization and accumulation of in vivo microdamage in human cortical bone. Bone. 2007; 40:612-8. (Pubitemid 46187218)
84. Arlot M, Burt-Pichat B, Roux J-P, et al. Microarchitecture influences microdamage accumulation in human vertebral trabecualr bone. J Bone Miner Res. 2008;23(10):1613-8.
85. Yeni YN, Hou FJ, Ciarelli T, et al. Trabecular shear stresses predict in vivo linear microcrack density but not diffuse damage in human vertebral cancellous bone. Ann Biomed Eng. 2003;31 (6):726-32.
86. Caler WE, Carter DR. Bone creep-fatigue damage accumulation. J Biomech. 1989;22:625-35. (Pubitemid 19266776)
87. Saito M, Marumo K. Collagen cross-links as a determinant of bone quality: a possible explanation for bone fragility in aging, osteoporosis, and diabetes mellitus. Osteoporosis Int. 2010;21:195-214.
88. Shiraki M, Kuroda T, Tanaka S, et al. Nonenzymatic collagen cross-links induced by glycoxidation (pentosidine) predicts vertebral fractures. J Bone Miner Metab. 2008;26(1):93-100. (Pubitemid 350307997)
89. Vashishth D, Gibson GJ, Khoury JI, et al. Influence of nonenzymatic glycation on biomechanical properties of cortical bone. Bone. 2001;28:195-201. (Pubitemid 32140975)
90. Vashishth D. The role of the collagen matrix in skeletal fragility. Curr Osteoporos Rep. 2007;5:62-6. (Pubitemid 46954743)
91. Tang SY, Zeenath U, Vashishth D. Effects of non-enzymatic glycation on cancellous bone fragility. Bone. 2007;40(4):1144-51. (Pubitemid 46386561)
92. Vashishth D. Hierarchy of bone microdamage at multiple length scales. Int J Fatigue. 2007;29:1024-33. (Pubitemid 46435702)
93. Sroga GE, Vashishth D. UPLC methodology for identification and quantitation of naturally fluorescent crosslinks in proteins: a study of bone collagen. J Chromatogr B. 2011;879:379-85. doi:10.1016/j.jchromb.2010.12.024.
94. Viguet-Carrin S, Roux JP, Arlot ME, et al. Contribution of the advanced glycation end product pentosidine and of maturation of type I collagen to compressive biomechanical properties of human lumbar vertebrae. Bone. 2006;39:1073-9. (Pubitemid 44528385)
95. Weis MA, Hudson DM, Kim L, et al. Location of 3-hydroxyproline residues in collagen types I, II, II, and V/XI implies a role in fibril supramolecualr assembly. J Biol Chem. 2010;285(4):2580-90.
96. Hauschka PV, Lian JB, Cole DEC, et al. Osteocalcin and matrix Gla protein: vitamin K-dependent proteins in bone. Physiol Rev. 1989;69(3):990-1047. (Pubitemid 19184853)
97. Hankenson KD, Bornstein P. The secreted protein thrombospondin-2 is an auticrin inhibitor of marrow stromal cell proliferation. J Bone Mineral Res. 2002;17:415-25. (Pubitemid 34171756)
98. George A, Veis A. Phosphorylated proteins and control over apatite nucleation, crystal growth, and inhibition. Chem Rev. 2008;108: 4670-93.